Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated January 22, 2004, reports full-year 2003 and fourth-quarter 2003 financial results. The company is a foreign private issuer headquartered in Paris, France. The report highlights continued strong sales growth driven by key therapeutic products and strategic alliances.
Key Financial Metrics
Revenue and Sales Growth
- 2003 Consolidated Sales: 8,048 million euros (up 15.6% on a comparable basis; 8.1% on a reported basis).
- 2003 Developed Sales: 10,560 million euros (up 20.4% on a comparable basis). Developed sales include consolidated sales plus sales generated under alliance agreements.
- Q4 2003 Consolidated Sales: 2,108 million euros (up 17.0% on a comparable basis; 10.8% on a reported basis).
- Top 10 Products (2003): Generated 5,420 million euros, representing 67.3% of consolidated sales, with 26.9% growth on a comparable basis.
Geographical Performance (2003 Consolidated Sales)
| Region | Sales (Million EUR) | Comparable Growth | Reported Growth |
|---|---|---|---|
| Europe | 4,693 | +10.4% | +9.0% |
| United States | 1,912 | +32.9% | +13.2% |
| Rest of the World | 1,443 | +13.1% | -0.8% |
Key Product Performance (2003 Consolidated Sales)
- Plavix(R): 1,325 million euros (+37.4% comparable).
- Stilnox(R)/Ambien(R): 1,345 million euros (+10.4% comparable).
- Eloxatin(R): 824 million euros (+125.8% comparable).
- Aprovel(R): 683 million euros (+24.4% comparable).
- Xatral(R): 222 million euros (+24.7% comparable).
Profit, Cash Flow, Debt, and Liquidity
The filing text does not provide specific values for net profit, operating cash flow, total debt, or liquidity ratios. Management commentary notes that accelerated growth in the second half of 2003 confirms the forecast for 2003 EPS growth (before exceptional items and goodwill amortization) despite unfavorable currency effects.
Material Changes vs. Prior Period
- Currency Impact: Unfavorable currency fluctuations reduced reported growth by 7.2 percentage points in 2003, primarily due to the weakening US dollar and certain Latin American and Asian currencies.
- Structural Changes: Changes in Group structure had a minor unfavorable impact of 0.3 percentage points on 2003 comparable sales.
- Portfolio Shift: The top 10 products increased their share of consolidated sales from 61.3% in 2002 to 67.3% in 2003. Conversely, the rest of the portfolio declined 2.4% on a comparable basis, impacted by the replacement of Ticlid(R) by Plavix(R) and the loss of Corotrope(R)/Primacor(R) sales to generics.
- Inventory Levels: US inventory levels for key products (Plavix, Ambien, Aprovel) were reported as sound, averaging close to 1.1 months as of December 31, 2003.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management confirmed that the accelerated growth in the second half of 2003 validates the forecast for 2003 EPS growth. Strong prescription growth in the US for Plavix(R) (+26.8%), Ambien(R) (+13.4%), and Avapro(R) (+14.9%) was cited as a key driver. The launch of Uroxatral(R) in the US in November 2003 is progressing in line with expectations.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Ability to expand profitably in the United States.
- Success of research and development programs.
- Protection of intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms, particularly in the US and France.
Investor Verification Checklist
- Non-GAAP Reconciliation: Verify the reconciliation between reported sales and comparable/developed sales, noting the significant impact of currency fluctuations (7.2 percentage points).
- EPS Forecast: Confirm the specific 2003 EPS growth forecast mentioned as "confirmed" but not explicitly quantified in this text.
- Alliance Revenue: Review the breakdown of "Developed Sales" to understand the portion of revenue derived from non-consolidated alliance partners (Bristol-Myers Squibb, Fujisawa, Organon).
- Product Lifecycle: Assess the long-term sustainability of growth for Eloxatin(R) and Plavix(R) given their high growth rates and the decline in older portfolio products.
- Inventory Health: Monitor future inventory levels in the US to ensure the "sound" levels reported (1.1 months) do not lead to future channel stuffing or destocking.